Reagent Generation for Bioanalytical Method Development on Biologics
ID: 75N95025R00007Type: Sources Sought
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NIDABethesda, MD, 20892, USA

NAICS

Medicinal and Botanical Manufacturing (325411)

PSC

HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH (AN11)

Original Source

https://sam.gov/opp/62ef1e103af0403db54b9fdbb745a5e5/view
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified sources for a potential contract focused on reagent generation for bioanalytical method development related to biologics. The primary objective is to obtain information on the availability and capability of companies to generate and deliver reagents, including anti-drug antibodies, that support the quantification of novel biologic drugs in various biological matrices. This initiative is crucial for advancing drug development processes and improving success rates in preclinical stages, with the Therapeutic Development Branch (TDB) at NIH playing a pivotal role in moving therapeutic candidates through the drug development pipeline. Interested parties must submit their capability statements by November 8, 2024, to Nick Niefeld at nick.niefeld@nih.gov, referencing sources sought notice number 75N95025R00007.

    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    Reagent Generation for Bioanalytical Method Development on Biologics
    Currently viewing
    Sources Sought
    Similar Opportunities
    Notice of Intent BD Rhapsody Single-Cell Analysis Reagent Kits
    Active
    Health And Human Services, Department Of
    Notice of Intent BD Rhapsody Single-Cell Analysis Reagent Kits The Department of Health and Human Services, Department of, National Institutes of Health, is planning to procure BD Rhapsody Single-Cell Analysis Reagent Kits. These kits are used for the manufacture of human cells and tissue-based products utilized in phase I/II clinical protocols for transplantation, adoptive immunotherapy, and gene therapy conducted in the Clinical Center at the NIH. The procurement includes a standing order for multi-type sequencing kits and reagents with a short shelf life. The contractor will be responsible for shipping the sufficient reagents and kits following the scheduled delivery dates. The shelf life of the sequencing reagents should be at least 3 months, and the shelf life of library generation kits should be at least 6 months. The contractor is also required to provide technical support for all kits and reagents at no additional cost. The period of performance for this procurement is from 5/1/2024 to 8/30/2024. The delivery schedule is overnight delivery Monday through Thursday to the Center for Cellular Engineering (CCE) at NIH/CC in Bethesda, MD. The vendor will be responsible for ensuring the safe transport of cryopreserved patient cells and maintaining the temperature and other parameters during the shipment of reagents and kits. The contractor will be paid per product delivered and is required to provide hard copies of proofs of each product delivered. Interested parties can submit their capabilities to the Office of Purchasing and Contracts by May 1st, 9:00 AM EST. Please note that this is not a request for proposal.
    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting proposals for Chemistry, Manufacturing, and Controls (CMC) services related to the development of drug products. The objective of this procurement is to secure high-quality formulated drug products to support preclinical, IND-enabling, and clinical studies, ensuring compliance with current Good Manufacturing Practices (cGMP). This initiative is critical for advancing therapeutic development and enhancing the drug development pipeline, which is vital for public health. Proposals are due by February 3, 2025, with a contract period extending from September 30, 2025, to July 31, 2031, and a maximum funding amount of $49,885,703. Interested parties can reach out to Michelle Cecilia at michelle.cecilia@nih.gov or Valerie Whipple at valerie.whipple@nih.gov for further information.
    Ongoing Monoclonal Antibodies and Plasmids Services through GENSCRIPT
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), intends to negotiate a sole-source contract with GenScript USA Inc. for ongoing monoclonal antibodies and plasmids services. The procurement aims to support the NIAID Laboratory of Immunogenetics (LIG) in advancing research on human B cells and the isolation of monoclonal antibodies, which are critical for developing new vaccine candidates against influenza. This contract is a continuation of existing services that require continuity for accurate comparison of results, and interested parties may submit capability statements via the NIAID electronic Simplified Acquisition Submission System (eSASS) by January 3, 2025, at 5:00 PM ET. For further inquiries, contact Dana Monroe at dana.monroe@nih.gov or call 406-375-9814.
    65--Illumina Reagents and Consumables
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Heart, Lung, and Blood Institute (NHLBI), intends to award a non-competitive contract to Illumina, Inc. for the supply of "Illumina Reagents and Consumables" essential for various sequencing and genotyping systems. This procurement is driven by the unique operational needs of NIH-owned systems, as confirmed by market research indicating that only Illumina can provide the proprietary reagents necessary to maintain research integrity and support ongoing studies. The contract performance period is set from September 3, 2025, to September 2, 2030, and interested parties may submit capability statements for review by January 6, 2025; however, this is not a solicitation for proposals. For further inquiries, interested parties can contact Ethan J. Mueller at ethan.mueller@nih.gov or by phone at +1 301 496 2153.
    SOURCES SOUGHT: Automated Cell Dissociation Apparatus
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified small businesses to provide an automated cell dissociation apparatus for the National Institute on Aging's Laboratory of Neurogenetics. The primary objective of this procurement is to acquire equipment capable of isolating single nuclei from human and mouse brain tissues, which is crucial for advancing research on neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Alzheimer's disease. The preferred model for this apparatus is the S2 Genomics Singulator 100 Cell Dissociation Platform, which must meet specific requirements including bench-top compatibility, single-use cartridges, and customizable software for protocol adjustments. Interested companies must submit their capability statements by January 17, 2025, to Rashiid Cummins at rashiid.cummins@nih.gov, ensuring they include all necessary documentation and adhere to the specified format.
    Assay Kits for Lumipulse instrument
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for the procurement of assay kits for the Lumipulse instrument, aimed at quantifying specific biomarkers related to Alzheimer's Disease. The acquisition includes a total of 4,410 assays for biomarkers abeta42, abeta40, and pTau 217, which will be utilized in research involving stored samples from the Baltimore Longitudinal Study of Aging (BLSA) to assess cognitive decline and neurodegeneration. This procurement is critical for advancing Alzheimer’s research and will be awarded as a firm fixed-price purchase order, with quotations due by 5:00 p.m. Eastern Time on January 8, 2025. Interested vendors should contact Iris Merscher at iris.merscher@nih.gov for further details.
    NIAID CLINICAL PRODUCTS CENTER (CPC)
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for a contract to provide pharmacy and pharmaceutical oversight for clinical trials, both nationally and internationally. The primary objective of this contract is to ensure the integrity of study products, participant safety, and compliance with pharmacy and pharmaceutical regulations throughout various NIH-funded clinical trials. This opportunity is critical for maintaining high standards in public health research, as it encompasses a wide range of services including product management, regulatory document maintenance, and clinical laboratory testing. Proposals are due by January 17, 2025, with the contract expected to commence on April 1, 2026, and run through March 31, 2027, potentially extending through 2033. Interested parties can contact Deborah Blyveis at blyveisd@niaid.nih.gov or Emily Bannister at emily.bannister@nih.gov for further information.
    National Institute of Environmental Health Sciences (NIEHS) Assessment of Immunotoxicity – In Vitro and In Vivo Assessment of Immune Function
    Active
    Health And Human Services, Department Of
    The National Institute of Environmental Health Sciences (NIEHS), part of the Department of Health and Human Services, is seeking proposals for a federal contract focused on the assessment of immunotoxicity through in vitro and in vivo evaluation of immune function. The objective is to provide comprehensive research services to evaluate how selected test agents may modulate immune responses, utilizing both established and innovative methodologies to reduce animal use in toxicology studies. This contract, anticipated to be a cost-plus-fixed-fee type, is expected to be awarded by September 2025, with a base period of one year and nine optional one-year extensions. Interested parties should direct inquiries to Adam Muhsin at adam.muhsin@nih.gov and monitor the Sam.gov website for the solicitation release, which is expected no sooner than 15 days from this notice.
    A--National Gene Vector Biorepository
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for the National Gene Vector Biorepository (NGVB) to support gene therapy research for the National Heart, Lung, and Blood Institute (NHLBI). The contract aims to provide essential resources and services, including administrative management, core laboratory activities, and compliance with FDA regulations and Good Laboratory Practices (GLP). This initiative is crucial for advancing gene therapy capabilities and ensuring the proper archiving of biological specimens and development of assays. Proposals must be submitted by January 10, 2025, and should include detailed technical and business plans, with specific formatting guidelines and a budget submission required. For further inquiries, interested parties can contact Ethan J. Mueller at ethan.mueller@nih.gov or +1 301 496 2153.
    NCI OA Special Notice of Subcontract Opportunity at the Frederick National Laboratory for Cancer Research
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Cancer Institute (NCI), has issued a Special Notice regarding a subcontract opportunity at the Frederick National Laboratory for Cancer Research (FNLCR) aimed at enhancing laboratory practices to meet Good Clinical Laboratory Practice (GCLP) standards. The primary objective is to engage a subcontractor to evaluate current laboratory operations, identify compliance gaps, and implement improvements related to sample management, data integrity, and overall laboratory quality standards. This initiative is crucial for ensuring the integrity of testing and data management, which will facilitate the approval of new vaccine recommendations and enhance the laboratory's quality management system. Interested parties should note that this notice is for informational purposes only, with responses treated as government property, and are encouraged to monitor SAM.gov for updates. The deadline for submissions is January 3, 2025, at noon EST, and inquiries can be directed to Jennifer Gnuschke at jennifer.gnuschke@nih.gov.